



Contacts: Meg McGilley  
Chief Financial Officer  
(858) 480-0402

Rob Whetstone  
PondelWilkinson Inc.  
(310) 279-5963

## Somaxon Pharmaceuticals to Present at the Cowen and Company 28<sup>th</sup> Annual Healthcare Conference

**SAN DIEGO, CA – March 12, 2008** – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that David Hale, executive chairman and interim chief executive officer, will present a company update at the Cowen and Company 28<sup>th</sup> Annual Healthcare Conference at The Boston Marriott Copley Place Hotel, in Boston, on Tuesday, March 18, 2008, at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time).

A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at [www.somaxon.com](http://www.somaxon.com) and at [http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=SOMX&item\\_id=1779966](http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=SOMX&item_id=1779966). The webcast will be archived and accessible for at least 14 days.

### **About Somaxon Pharmaceuticals**

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia, and has submitted a New Drug Application for this product candidate to the U.S. Food and Drug Administration.

For more information, please visit the company's web site at [www.somaxon.com](http://www.somaxon.com).

###